EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitHistorischer BeitragOpen Access · CC BY-NC-ND 4.0

From bench to bedside: the untold story behind the clinical development of enoxaparin

Jack Hirsh, Noel Chan

Journal of Thrombosis and Haemostasis · 2026

DOI: 10.1016/j.jtha.2026.01.013 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026. Verfasst von Jack Hirsh und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, McMaster University, Hamilton, Ontario, Canada. Hauptthemen laut MEDLINE: Enoxaparin, Anticoagulants, Fibrinolytic Agents, Venous Thrombosis. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The path to the development of enoxaparin (Lovenox/Clexane), one of the most widely used low-molecular-weight heparins worldwide, was far from smooth. This narrative review, presented from the personal perspective of the senior author who lived this journey, describes the pivotal research conducted at McMaster University in Canada that transformed enoxaparin from a promising laboratory compound into a cornerstone of prevention and treatment of thrombosis. The story begins in the late 1970s with the observation that low-molecular-weight heparin, produced through controlled depolymerization, exhibited antithrombotic efficacy comparable with unfractionated heparin, with a reduced risk of bleeding in animal models. It concludes in the 1990s with the successful evaluation in clinical trials and the regulatory approval of enoxaparin for the prevention of deep vein thrombosis after orthopedic surgery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EnoxaparinAnticoagulantsFibrinolytic AgentsVenous ThrombosisTranslational Research, BiomedicalBlood CoagulationHumansAnimalsHistory, 20th CenturyHemorrhageHistory, 21st CenturyTreatment Outcome

Stichwörter der Autor:innen

enoxaparinheparinlow-molecular-weight heparinthromboprophylaxisvenous thromboembolism

Substanzen

EnoxaparinAnticoagulantsFibrinolytic Agents

Autor:innen und Institutionen

  • Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
  • Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Population Health Research Institute, Hamilton, Ontario, Canada; Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada. Elec…

Zitieren

APA

Hirsh, J., & Chan, N. (2026). From bench to bedside: the untold story behind the clinical development of enoxaparin. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2026.01.013

Vancouver

Hirsh J, Chan N. From bench to bedside: the untold story behind the clinical development of enoxaparin. Journal of Thrombosis and Haemostasis. 2026. doi:10.1016/j.jtha.2026.01.013

BibTeX
@article{Hirsh2026,
  author = {Hirsh, Jack and Chan, Noel},
  title = {From bench to bedside: the untold story behind the clinical development of enoxaparin},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2026},
  doi = {10.1016/j.jtha.2026.01.013}
}
Kostenlos starten →